

Resonance Health Announces Agreement with Novartis

Resonance Health Announces 2-Year FerriScan[®] Master Service Agreement ++ Company Expands Global Access to FerriScan[®] (R₂ MRI) as a non-invasive measure of liver iron concentration (LIC) in patients with transfusional iron overload disorders.

Resonance Health (RHT) has signed a 2-year Master Service Agreement with Novartis AG (Basel, Switzerland) and Novartis Pharmaceutical Corporation (U.S.) to provide FerriScan[®] (R₂ MRI) services to Novartis worldwide. This agreement expands the strategic collaboration between Resonance Health and Novartis which began in 2004 as part of a clinical development program for their iron chelation product which is currently approved in more than 100 countries for transfusional iron overload.

FerriScan[®] is a non-invasive, MRI-based technology that is indicated for the analysis of liver iron concentration in individuals with, or suspected of having, systemic iron overload. It is used to provide a definitive diagnosis of iron overload and for monitoring liver iron burden as part of ongoing clinical management of patients with thalassaemia, sickle cell disease, myelodysplastic syndrome (MDS) and hereditary haemochromatosis. FerriScan[®] received U.S. FDA clearance in 2005 and has regulatory clearance in Australia (Therapeutic Goods Administration), Europe (CE Mark), Canada (Health Canada) and New Zealand (MedSafe).

“This Master Service Agreement between Resonance Health, Novartis AG and Novartis Pharmaceutical Corporation will be extremely important for the overall management and monitoring of patients with transfusional iron overload disorders and expands our strategic alliance with Novartis” said Liza Dunne, Managing Director, Resonance Health. “Using a non-invasive, validated tool to obtain an accurate assessment of iron levels in the management of these patient populations may help to reduce or eliminate more serious downstream iron-related health complications. This strategic alliance with Novartis will result in increased awareness of FerriScan[®] worldwide and will continue to demonstrate the commercial value of the test in key international markets.”

FerriScan[®] has gained widespread clinical support and is listed in a growing number of clinical practice guidelines by a number of U.S. and international medical societies. FerriScan[®] is currently available in over 20 countries and is delivered as a fee for service through a central image analysis laboratory.

This agreement represents an opportunity to provide FerriScan[®] to many patients worldwide with iron overload conditions who may not otherwise have access to this technology.

By Order of the Board
Resonance Health Limited

DISCLAIMER

The foregoing release contains forward-looking statements that can be identified by terminology such as “will” or similar expressions, or by express or implied discussions regarding potential new indications or labelling in additional markets, or regarding potential future revenues from FerriScan[®] or Exjade™. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.

For further information please contact:

Resonance Health Ltd

Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@resonancehealth.com

Stewart Washer
Chairman
T: +61 8 9286 5300
E: sjwasher@bigpond.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a healthcare company providing central image laboratory services utilising advanced technology for the analysis of medical images and providing associated CRO services. Its patented technology FerriScan[®] provides a safe and accurate alternative for measuring liver iron concentration, a significant issue for patients with iron overload.